Asterias Biotherapeutics Inc. Series A
AST
AST was delisted on the 7th of March, 2019.
46 hedge funds and large institutions have $4.73M invested in Asterias Biotherapeutics Inc. Series A in 2018 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 15 reducing their positions, and 15 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less funds holding
Funds holding: 54 → 46 (-8)
53% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 15
58% less capital invested
Capital invested by funds: $11.3M → $4.73M (-$6.56M)
60% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 15
77% less call options, than puts
Call options by funds: $9K | Put options by funds: $39K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NFC
Northeast Financial Consultants
Westport,
Connecticut
|
+$599K |
| 2 |
Renaissance Technologies
New York
|
+$151K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
+$20.7K |
| 4 |
FCMT
Founders Capital Management (Texas)
Houston,
Texas
|
+$4.15K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$1.91K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$841K |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$341K |
| 3 |
Millennium Management
New York
|
-$305K |
| 4 |
Goldman Sachs
New York
|
-$75K |
| 5 |
ECM
Element Capital Management
New York
|
-$74K |
AST Hedge Fund Activity: Q4 2018 in Review
46 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q4 2018, worth a combined $4.73M — down 58% from $11.3M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of AST and 7 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 6 added.
The largest buyer was Northeast Financial Consultants, opening a new position worth an estimated $599K. The largest seller was Vanguard Group, cutting an estimated $841K.
- 46 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q4 2018, down from 54 in Q3 2018.
- Funds reported $4.73M of Asterias Biotherapeutics Inc. Series A stock for Q4 2018, down 58% quarter-over-quarter.
- 7 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q4 2018 and 15 closed out, a net change of -8 holders.
- The largest Asterias Biotherapeutics Inc. Series A buyer in Q4 2018 was Northeast Financial Consultants, an estimated $599K added.
- The largest Asterias Biotherapeutics Inc. Series A seller in Q4 2018 was Vanguard Group, an estimated $841K sold.
Based on aggregated 13F filings for Q4 2018.